Last10K.com

Inhibikase Therapeutics, Inc. (IKT) SEC Filing S-1 IPO Report

SEC Filings

IKT Registration of Securities

  • S-1 Registration of Securities June 2021

Inhibikase Therapeutics, Inc.

CIK: 1750149 Ticker: IKT

View differences made from one to another to evaluate Inhibikase Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this S-1 Registration of Securities to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Inhibikase Therapeutics, Inc..

Continue

Assess how Inhibikase Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Inhibikase Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this S-1 Registration of Securities

Cover
Condensed Balance Sheets
Condensed Balance Sheets (Parenthetical)
Condensed Statements Of Cash Flows
Condensed Statements Of Operations
Condensed Statements Of Stockholders' Equity (Deficit)
Basis Of Presentation And Significant Accounting Policies
Basis Of Presentation And Significant Accounting Policies (Policies)
Basis Of Presentation And Significant Accounting Policies - Additional Information (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Summary Of Potential Milestone Payments (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Net Deferred Tax Asset (Detail)
Income Taxes - Schedule Of Reconciliation Of U.S. Federal Statutory Rate (Detail)
Liquidity And Going Concern
Liquidity And Going Concern - Additional Information (Details) (Detail)
Nature Of Business
Nature Of Business - Additional Information (Detail)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Summary Of Calculation Of Basic And Diluted Net Loss Per Share Applicable To Common Stockholders (Detail)
Net Loss Per Share - Summary Of Shares Excluded From Calculation Of Diluted Net Loss Per Share Applicable To Common Stockholders (Detail)
Notes Payable
Notes Payable (Tables)
Notes Payable - Additional Information (Detail)
Notes Payable - Summary Of Future Principal Payments On Notes Payable (Detail)
Notes Payable - Summary Of Notes Payable Outstanding (Detail)
Simple Retirement Account For Employees (The "Simple Ira")
Simple Retirement Account For Employees (The "Simple Ira") - Additional Information (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Schedule Of Assumptions Used In Black-Scholes Valuation Model To Estimate Fair Value Of Stock Options (Detail)
Stock-Based Compensation - Summary Of Stock Options Activity (Detail)
Stock-Based Compensation - Summary Of Stock-Based Compensation Expense For Stock Options Granted To Employees And Non-Employees (Detail)
Stockholders' Deficit
Stockholders' Deficit - Additional Information (Detail)
Supplemental Balance Sheet Information
Supplemental Balance Sheet Information (Tables)
Supplemental Balance Sheet Information - Schedule Of Accrued Expenses And Other Current Liabilities (Detail)
Warrants
Warrants - Additional Information (Detail)

Material Contracts, Statements, Certifications & more

Inhibikase Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: IKT
CIK: 1750149
Form Type: S-1 Registration of Securities
Accession Number: 0001193125-21-188903
Submitted to the SEC: Fri Jun 11 2021 4:24:09 PM EST
Accepted by the SEC: Fri Jun 11 2021
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ikt/0001193125-21-188903.htm